CHRS Coherus BioSciences Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1, 2016

 

 

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-36721		27-3615821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 649-3530

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 8.01

Other Events

On February 1, 2016, Coherus BioSciences, Inc. announced that CHS-1701, its pegfilgrastim (Neulasta^®) biosimilar product candidate, met its two primary immunogenicity endpoints in a double-blind, randomized, two-period, parallel-arm clinical study. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

Exhibit No.		Description
99.1		Press release titled “Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study” dated February 1, 2016

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 1, 2016				COHERUS BIOSCIENCES, INC.
				By:		/s/ Jean-Frédéric Viret
				Name:		Jean-Frédéric Viret
				Title:		Chief Financial Officer

---

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release titled “Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study” dated February 1, 2016

Exhibit 99.1

Coherus Announces CHS-1701 (Neulasta^® Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study

REDWOOD CITY, Calif., Feb. 1, 2016 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ:CHRS) today announced that CHS-1701, a proposed biosimilar of Neulasta^® (pegfilgrastim), met both primary endpoints in a double-blind, randomized, two-period, parallel-arm clinical study in 303 healthy subjects.

This study assessed the immunogenicity of two sequential 6 mg subcutaneous doses of CHS-1701 compared with two sequential 6 mg subcutaneous doses of Neulasta^®. The primary outcome measures were based on testing for the development of neutralizing antibodies and determination of the percent difference between the test articles in anti-drug antibody (ADA) response.

“This study successfully met both pre-specified immunogenicity endpoints. First, no neutralizing antibodies were detected in either group. Second, the percent difference in ADA response between the test articles fell within the pre-specified success criteria for biosimilarity,” said Barbara Finck, M.D., Chief Medical Officer of Coherus. “Further, there were no clinically meaningful differences in the safety profiles of the two products.”

“The success of this rigorous study is a key achievement in support of our planned Biologics License Application (BLA) filing,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “To the best of our knowledge, we will be the only biosimilar company to have comparative immunogenicity data with Neulasta in a healthy population with an intact immune system. As the lead asset of our oncology therapeutic franchise, CHS-1701 will spearhead our commercialization efforts for oncology biosimilars in the United States. We expect to complete our follow-on PK/PD study for this product late in the first half of this year and move forward with BLA filing directly thereafter.”

About Coherus BioSciences, Inc.

Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.

---

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, product development, and the potential benefits of and demand for its products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including Coherus’ expectations regarding its ability to advance its CHS-1701 biosimilar drug candidate, file a BLA for CHS-1701 and successfully launch the commercialization of CHS-1701 and other oncology biosimilars. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates, as well as possible patent litigation. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 10, 2015, and its future periodic reports to be filed with the Securities and Exchange Commission.

Neulasta^® is registered trademarks of Amgen Inc.

INVESTOR AND MEDIA CONTACT:

Keith Vendola, M.D.

kvendola@coherus.com

+1 (650) 437-6239